Beam Therapeutics (BEAM)

• Market cap: $1.93B
• 1 day: -8.77%
• 5 days: -13.19%
• 1 month: -19.46%
• 3 months: -12.37%
• 6 months: -9.06%
• Year to date: -5.67%
• 1 year: -7.17%
• 5 years: 24.27%
• 10 years: 24.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Employees: 374

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

94% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $6.22M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

40% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 20

5% more capital invested

Capital invested by funds: $1.85B [Q2] → $1.95B (+$97M) [Q3]

3% more funds holding

Funds holding: 213 [Q2] → 219 (+6) [Q3]

7% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 67

0.57% more ownership

Funds ownership: 96.05% [Q2] → 96.61% (+0.57%) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $24 3% upside
• Avg. target: $42 79% upside
• High target: $80 243% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 58 / 161 met price target	243% upside $80	Buy Reiterated	9 Dec 2024
RBC Capital Luca Issi 20% 1-year accuracy 11 / 56 met price target	3% upside $24	Sector Perform Maintained	6 Nov 2024
Leerink Partners Rick Bienkowski 14% 1-year accuracy 1 / 7 met price target	67% upside $39	Outperform Upgraded	6 Nov 2024
Scotiabank Greg Harrison 41% 1-year accuracy 11 / 27 met price target	3% upside $24	Sector Perform Initiated	16 Oct 2024